1. Home
  2. STOK vs SHEN Comparison

STOK vs SHEN Comparison

Compare STOK & SHEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STOK
  • SHEN
  • Stock Information
  • Founded
  • STOK 2014
  • SHEN 1902
  • Country
  • STOK United States
  • SHEN United States
  • Employees
  • STOK N/A
  • SHEN N/A
  • Industry
  • STOK Biotechnology: Pharmaceutical Preparations
  • SHEN Telecommunications Equipment
  • Sector
  • STOK Health Care
  • SHEN Telecommunications
  • Exchange
  • STOK Nasdaq
  • SHEN Nasdaq
  • Market Cap
  • STOK 721.4M
  • SHEN 744.2M
  • IPO Year
  • STOK 2019
  • SHEN N/A
  • Fundamental
  • Price
  • STOK $9.36
  • SHEN $11.68
  • Analyst Decision
  • STOK Strong Buy
  • SHEN Strong Buy
  • Analyst Count
  • STOK 8
  • SHEN 1
  • Target Price
  • STOK $21.83
  • SHEN $26.00
  • AVG Volume (30 Days)
  • STOK 933.4K
  • SHEN 260.4K
  • Earning Date
  • STOK 11-05-2024
  • SHEN 02-19-2025
  • Dividend Yield
  • STOK N/A
  • SHEN 0.86%
  • EPS Growth
  • STOK N/A
  • SHEN 5657.38
  • EPS
  • STOK N/A
  • SHEN 3.75
  • Revenue
  • STOK $16,742,999.00
  • SHEN $328,807,000.00
  • Revenue This Year
  • STOK $105.42
  • SHEN $17.88
  • Revenue Next Year
  • STOK N/A
  • SHEN $13.58
  • P/E Ratio
  • STOK N/A
  • SHEN $3.23
  • Revenue Growth
  • STOK 81.08
  • SHEN 21.23
  • 52 Week Low
  • STOK $4.09
  • SHEN $11.39
  • 52 Week High
  • STOK $17.58
  • SHEN $22.27
  • Technical
  • Relative Strength Index (RSI)
  • STOK 36.22
  • SHEN 33.33
  • Support Level
  • STOK $8.42
  • SHEN $11.39
  • Resistance Level
  • STOK $9.77
  • SHEN $11.99
  • Average True Range (ATR)
  • STOK 0.66
  • SHEN 0.42
  • MACD
  • STOK -0.09
  • SHEN -0.07
  • Stochastic Oscillator
  • STOK 28.40
  • SHEN 18.01

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.

About SHEN Shenandoah Telecommunications Co

Shenandoah Telecommunications Company, with its subsidiaries, provides various broadband communication products and services via its wireless, cable, fiber optic, and fixed wireless networks to customers in the Mid-Atlantic United States. The company operates through two business units: tower and broadband. The tower segment leases company-owned cell tower spaces to other wireless communication providers, while the broadband segment provides broadband Internet, video, and voice services to residential and commercial customers. The broadband segment generates the vast majority of the company's revenue, with the bulk of sales flowing from residential and small, and medium businesses within the broadband unit.

Share on Social Networks: